Background. Longer and more frequent dialysis sessions have demonstrated excellent survival and clinical advantages, while online haemodiafiltration (OL-HDF) provides the most efficient form of dialysis treatment. The aim of this study was to evaluate the beneficial effects of a longer (nocturnal) and more frequent (every-other-day) dialysis schedule with OL-HDF at the same or the highest convective volume.
Introduction
Dialysis patients have a high mortality and morbidity rate, and their remaining life expectancy is lower than that of the general population. Mortality in patients undergoing a conventional dialysis regimen of three 4-h sessions/week is quadruple than that of the general population >65 years old [1, 2] and so new therapeutic regimens are required to improve patient survival, reduce dialysis time and frequency and develop techniques with a higher depurative capacity.
The results of the Tassin experience of long slow-flow haemodialysis (HD) sessions were first reported 25 years ago and showed excellent fluid and blood pressure control with the highest survival rates achieved at that time [3] . Since then, multiple publications have evaluated the superiority of long-duration HD over conventional therapy in blood pressure control, reduction of left ventricular hypertrophy (LVH) and reduced serum phosphate levels, often allowing phosphate binders to be discontinued [2, 4, 5] .
A thrice-weekly frequency of HD sessions was established in the 1960s and has been widely accepted and maintained for logistic, pragmatic and economic reasons. However, there is growing interest in the use of more frequent dialysis schedules since long-term experiences of higher frequencies have shown good results [6] [7] [8] [9] [10] [11] . In 1972, the Lecce centre started a scheme of every-other-day dialysis to avoid long weekend periods and reported a 60% survival at 10 years with a lower incidence of ischaemic heart disease, stable high depurative efficiency and improvements in anaemia, acid-base and nutritional status [8] .
Online haemodiafiltration (OL-HDF) could offer an optimal form of extracorporeal treatment for dialysis patients. This technique, which combines diffusion with high convection, provides the highest clearances per unit of surface area for small, medium and large molecules. The same dialysis fluid, free of toxins and pyrogens, is used as a substitution solution. This technique is safe and well tolerated and provides good clinical results [12] [13] [14] [15] .
In this study, we sought to combine a more physiological and effective dialysis schedule-long (nocturnal) and more frequent (every-other-day) dialysis-with the dialysis modality offering the highest solute and uraemic toxin removal (OL-HDF). The aim of this study was to switch patients from standard, 4-to 5-h, thrice-weekly OL-HDF to 7-to 8-h, every-other-day OL-HDF in a crossover study with the same or higher convective volume and to evaluate the impact of this schedule on solute removal and analytical and clinical outcomes.
Materials and methods
This was a single-centre, crossover prospective study. Twenty-six patients, 18 men and 8 women, with a mean age of 49.2 AE 14 years (range , who were stable on HD over a period of 38.7 AE 70 months and on standard 4-to 5-h thrice-weekly OL-HDF for at least 3 months (6.8 AE 7 months) were switched to nocturnal every-other-day OL-HDF, 7-8 h per session and were randomly assigned to receive 6 months of the same convective volume (20-30 L; Group A) or a higher convective volume (35-50 L; Group B), followed by a further 6 months of the other convective volume ( Figure 1 ). The underlying renal diseases were chronic glomerulonephritis in seven patients, diabetic nephropathy in five, polycystic kidney disease in five, nephroangiosclerosis in three, systemic diseases in two, urologic disease in two, chronic tubulo-interstitial nephritis in one and undiagnosed nephropathy in one. All patients signed informed consent forms approved by the hospital's Research Committee.
Patient inclusion criteria consisted of stable patients under HD with good vascular access and with good prospects for improved occupational, psychological and social rehabilitation. For this reason, the patients enrolled in this study were younger than the general dialysis population.
Baseline OL-HDF parameters were bicarbonate buffer, 1.4-1.8 m 2 highflux helixone filter (FX60 or FX80; Fresenius), blood flow (Q b ) 440 AE 33 mL/min (range 400-500 mL/min), dialysate flow (Q d ) 800 mL/min, infusion flow (Q i ) included, which ranged from 90 to 110 mL/min, and a Fresenius 4008 or 5008 dialysis monitor. Re-infusion was always performed in a post-dilutional mode. All patients had native arteriovenous fistulae. The dialysers were not re-used. In all patients, 15-gauge needles were used. During the study, notable changes were a reduction of Q d to 500 mL/min and a slightly lowered surface area filter (Table 1) .
The following urea kinetic parameters were calculated: urea reduction ratio (URR), Kt [16] , single-pool second-generation Daugirdas Kt/V (spKt/V) [17] , equilibrated Kt/V (eKt/V) [18] , standard Kt/V (stdKt/V) [19] , time-averaged concentration (TAC) and normalized protein catabolic rate (nPCR).
To compare removal capacity between the two treatment modes, removal of a wide spectrum of solutes was studied. Pre-and post-dialysis concentrations of urea (60 Da), creatinine (113 Da), b 2 -microglobulin (11 800 Da), myoglobin (17 000 Da), prolactin (23 000 Da) and a 1 -acid glycoprotein (44 000 Da) were measured. Pre-treatment blood samples were drawn immediately after access needle insertion. Post-treatment samples were drawn from the arterial blood line 60 s after the blood flow rate was decreased to 50 mL/min. The pre-to post-treatment reduction ratios in plasma for b 2 -microglobulin, myoglobin, prolactin and a 1 -acid glycoprotein were determined after post-dialysis concentrations were corrected using the method of Bergström and Wehle [20] [21] .
This study was also designed to evaluate biochemical and clinical outcomes. The last month on conventional, 4-to 5-h, thrice-weekly OL-HDF, during which treatment conditions were unchanged, was taken as the baseline period before patients were switched to nocturnal every-otherday OL-HDF. Treatment was carried out >12 months. Each month at midweek, pre-dialysis plasma analyses for haemoglobin, haematocrit, ferritin, transferrin saturation, urea, creatinine, sodium, potassium, uric acid, bicarbonate, calcium, phosphorus, intact parathyroid hormone, serum protein, albumin, pre-albumin, transferrin, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, triglycerides, b 2 -microglobulin, myoglobin, C-reactive protein and glycated haemoglobin were carried out as well as a quarterly analysis of homocysteine, interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor.
All patients completed a fatigue index questionnaire on the intensity, duration and frequency of post-dialysis fatigue [22] at baseline and every 6 months. Fatigue intensity was scored as follows: 1, none; 2, mild (noticeable but without effect); 3, moderate (felt sluggish); 4, severe (required rest) or 5, overwhelming (slept). Fatigue duration was scored as follows: 1, none; 2, mild (1-4 h); 3, moderate (6-12 h); 4, severe (12-24 h) or 5, overwhelming (>24 h). Pre-dialysis blood pressure was measured immediately before treatment with an automatic blood pressure monitor. LVH was evaluated by echocardiographic assessment. Measurements included left ventricular wall mass (LVM), LVM index (LVMI) and ejection fraction. All studies were performed and analysed by the same experienced cardiologist, who was blinded to the patients' data. Studies were performed on a midweek non-dialysis day and LVMI was calculated using the formula of Devereux and Reichek, modified in accordance with the recommendations of the American Society of Echocardiography [23] .
Randomized Patients (n=26)
The results were expressed as the arithmetic mean AE SD. Each patient served as his/her own control. Student's t-test and analysis of variance test (repetitive data) were used in the analysis of differences in quantitative variables. A value of P <0.05 was considered statistically significant.
Results
The duration of dialysis sessions increased from 273 AE 19 min (range 240-300 min) at baseline to 471 AE 22 min (range 420-480 min) in nocturnal every-other-day OL-HDF (P < 0.01). Q b was 439 AE 33 mL/min at baseline versus 427 AE 36 mL/min at 6 months and 421 AE 32 mL/min at 12 months (P < 0.05). The groups were randomized to receive different convective volumes (Figure 2 ). The baseline volume was 26.1 AE 2 L, which increased to 35.7 AE 9.6 L after 3 months (Group A 27.0 AE 2.4 L and Group B 44.3 AE 4.7 L).
All patients who were working (56%) during the baseline period continued to work throughout the study with practically no absenteeism. All patients completed the study except for two in Group B because one received a renal transplant and the other had a stroke and was sent to a rehabilitation centre because he lived alone. Nocturnal every-other-day OL-HDF was well accepted and tolerated. Fatigue intensity scores showed no significant changes: scores decreased from 2.92 AE 1.6 at baseline to 2.25 AE 1.1 in Group A (non significant) and 1.75 AE 1.0 to 1.75 AE 0.9 in Group B (non significant) at 12 months, while fatigue duration scores varied from 2.42 AE 1.1 at baseline to 2.08 AE 0.9 in Group A and 1.58 AE 0.5 to 1.58 AE 0.7 in Group B at 12 months (non significant).
Urea kinetics
At baseline, the patients received a high dialysis dose, which increased markedly throughout the study when the patients were switched to nocturnal every-other-day OL-HDF. Kt (L), URR (%), spKt/V, eKt/V, stdKt/V and TAC (mg/dL) were significantly increased with respect to baseline ( Table 2) . 
Haematological parameters
There were no changes in haemoglobin, haematocrit, leucocyte count or transferrin saturation (Table 3) . At baseline, ferritin levels significantly differed between the two groups: ferritin levels were lower in Group B (191 AE 133 ng/mL) than in Group A (457 AE 264 ng/mL, P < 0.05). Three months later, after iron adjustments, there were no significant differences and these results were sustained during the remainder of the study, with the same iron dose at the end of the protocol. Although the total dose of erythropoiesisstimulating agents (ESA), using a conversion ratio for darbepoetin alfa to epoetin of 200:1 and the erythropoietin resistance index had a decreasing tendency over the 12-month period, there were no significant differences. This tendency was especially observed in Group B, which showed lower ferritin levels than Group A. Of the 24 patients, at baseline, only one patient (4%) did not receive ESA, while at 12 months, 7 patients (29%) were not receiving ESA.
Biochemical parameters
Bicarbonate levels were significantly higher in all patients with respect to baseline values. Blood urea nitrogen (BUN) and creatinine values at 3, 6, 9 and 12 months significantly decreased in nocturnal every-other-day OL-HDF. There were no changes in sodium, potassium, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride and uric acid levels during the study period (Table 4 ). However, in Group A, HDL values rose significantly from 42.1 AE 7 mg/ dL at baseline to 47.7 AE 10 mg/dL at 3 months and this change was maintained at the 12-month outcome (P < 0.01) ( Table 4 ). At baseline, two patients (one in each group) were taking statins and after the study began, three other patients (two in Group A and one in Group B) initiated this treatment.
Baseline pre-dialysis b 2 -microglobulin levels did not differ between the two groups during the study. In Group A, levels were 25.5 AE 7 mg/L at baseline and 23.4 AE 5, 23.7 AE 5, 24.2 AE 5 and 23.8 AE 4 mg/L at 3, 6, 9 and 12 months, respectively; in Group B, levels were 27.6 AE 14 at baseline and were 24.5 AE 10, 28.0 AE 13, 27.6 AE13 and 27.9 AE 13 at 3, 6, 9 and 12 months, respectively. 
Bone and mineral parameters
Phosphorus levels significantly decreased and phosphate binders markedly decreased (Table 5) . Pre-dialysis serum phosphorus significantly decreased in the overall group from 4.93 AE 1.5 to 3.74 AE 1 mg/dL at the end of the study, and similar behaviour was observed in post-dialysis serum phosphorus (Table 5 ). Phosphate binders were reduced from 3.38 AE 3.7 tablets/day at baseline to 0.33 AE 1.3 tablets/day after 3 months and 0.13 AE 0.6 tablets/day after 12 months (P < 0.01) in nocturnal every-other-day OL-HDF ( Figure 3 ). The decrease in serum phosphorus was such that 55% of the patients required the addition of phosphorus supplements [FosfosodaÒ (Casen fleet laboratories, Utebo, (Table 5 ).
Nutritional and inflammatory parameters
Body weight (measured as dry weight after dialysis) showed an overall increase in the group taken as a whole from 70.1 AE 19 to 72.2 AE 19 kg (P < 0.01). A quarterly increment in Groups A and B is illustrated in Figure 4 , showing an increase of 2.4 kg in Group A and 1.9 kg in Group B at the end of the study. This weight increase was accompanied by an increasing tendency in interdialytic weight gain and protein intake. There were no significant changes in the following nutritional and inflammatory parameters: nPCR, total protein, albumin, pre-albumin and transferrin, C-reactive protein, homocysteine, glycated haemoglobin, IL-1, IL-6 and tumour necrosis factor (Tables 6  and 7) .
Cardiovascular parameters
During the study period, pre-dialysis systolic blood pressure decreased in both groups taken as a whole from baseline with a significant change at 12 months (132 AE 25 to 121.8 AE 26; P < 0.05). No significant changes were observed in diastolic or mean blood pressure (Table 8 ). There were significant differences in anti-hypertensive drugs between the two groups at baseline: practically, no antihypertensive drugs were prescribed in Group A (0.25 AE 0.5) compared with Group B (1.42 AE 1.4, P < 0.05). The number of anti-hypertensive drugs was significantly reduced from baseline to the 12-month evaluation (from 1.42 AE 1.4 to 0.25 AE 0.9 in Group B and from 0.83 AE 1.2 to 0.17 AE 0.6 in the whole group) ( Table 8 ).
The echocardiographic parameters in Table 8 show that there was a significant rise in ejection fraction from 54.5 AE 9 to 62.2 AE 10% in Group A (P < 0.05) and 57.9 AE 8 to 62.7 AE 8% in the whole group (P < 0.01). LVM significantly decreased in Group B at the 6-and 12-month evaluations from 260 AE 62 g (baseline) to 219 AE 69 and 222 AE 44 g, respectively (P < 0.05). LVMI was also decreased in Group B at the 6-and 12-month evaluations as well as in the whole group at the end of the study from 139 AE 36 to 123 AE 22 g/m 2 (P < 0.05).
Solute removal
The mean session values for urea and creatinine reduction ratios were significantly increased in both groups on 
every-other-day nocturnal OL-HDF compared with baseline values (Figure 5).
A different pattern was observed in the b 2 -microglobulin reduction ratio, which significantly increased after 6 months of the higher convective volume (35-50 L) in both groups on nocturnal every-other-day OL-HDF. In Group A, the baseline value increased from 80.3 AE 4.2 to 85.6 AE 3.2% at 3 months and 84.2 AE 4.3% at 6 months (P < 0.01). In Group B, this increment was observed at 9 and 12 months ( Figure 6 ).
Another pattern was observed in myoglobin and prolactin reduction ratios (Figure 7) , which significantly decreased with nocturnal every-other-day OL-HDF during the 6-month period with the same (20-30 L) convective volume. However, no significant changes were found in the myoglobin and prolactin reduction ratios when the higher convective volume (35-50 L) was used.
Finally, a 1 -acid glycoprotein reduction ratios, the highest molecular weight measured, showed a small but significant increase with nocturnal every-other-day OL-HDF. In Group A, the baseline value of 4.2 AE 8% increased to 13.3 AE 6% (P < 0.01), 13.4 AE 8% (P < 0.01), 14.2 AE 7% (P < 0.01) and 15.0 AE 6% (P < 0.01) at 3, 6, 9 and 12 months, respectively; in Group B, these values were 7.5 AE 7% to 12.1 AE 7%, 10.0 AE 6%, 18.4 AE 8% (P < 0.01) and 14.6 AE 7%, respectively.
Discussion
An every-other-day HD model was used by the Lecce group since 1972 to avoid long weekend periods but no other experiences have been reported. Thrice-weekly prolonged HD has been used by the Tassin group for >28 years, and interest in this modality has grown in the last 5 years with several publications from Canada [4] , USA [24] , UK [25] , Germany [5] and Turkey [26] . Nowadays, OL-HDF provides the most efficient form of dialysis and the use of this modality has markedly increased in Europe and Asia in recent years with abundant publications.
To our knowledge, our study is the first experience reported in the literature to combine long HD sessions, everyother-day dialysis and the dialysis modality that offers the highest solute and uraemic toxin removal (OL-HDF). This was a cross-sectional study, which compared the effect of a switch from 4 to 5 h thrice-weekly OL-HDF to 7-8 h nocturnal every-other-day OL-HDF with the same (20-30 L) or higher (35-50 L) convective volume. This protocol achieved adequate social and occupational rehabilitation and clinical and biochemical parameters, with remarkable improvement in nutritional status, regression of LVH, phosphate and hypertension control and a marked reduction in Nocturnal every-other-day OL-HDF 1625 phosphate binders and anti-hypertensive medication. Importantly, during the baseline period, the patients received a high dialysis dose; and anaemia, inflammation and blood pressure were well controlled. A retrospective analysis of the United States renal data system database of patients entering dialysis from 1992 to 2003 found that the major factor affecting employment was patients' co-morbidities and recommended treating anaemia before patients entered dialysis and educating them on work-friendly home dialysis [27] . There was a significant relationship between the length of dialysis sessions, level of fatigue and amelioration of uraemia-associated clinical parameters [28] . In nocturnal HD, patients are free to carry out their routine activities during the day, which enhances their quality of life. According to Pipkin et al. [29] , lack of patient or family motivation and fear of the dialysis process are surmountable barriers to the acceptance of home HD and the in-centre nocturnal HD option is a good alternative that should be encouraged because of its clinical, social and occupational rehabilitation benefits.
Other studies with prolonged duration were performed with a Q b of between 200 and 400 mL/min, a Q d of 500-800 mL/min and elevated dialysis dose. The Tassin experience [3] reported an spKt/V of 1.67 in 445 patients with a mean Q b of 220 mL/min and Q d of 500 mL/min. In 2009, Bugeja et al. [4] and Powell et al. [25] reported a URR of 89 and 77% in 39 and 146 patients, respectively, with a Q b of 300-400 mL/min and Q d of 500-700 mL/min. Finally, Ok et al. [26] , Lacson et al. [24] and David et al. [5] reported an eKt/V of 1.87, 2.21 and 2.70 in 153, 655 and 13 patients, respectively. Our study represents a higher dialysis dose per session than that reported by other groups with thrice-weekly dialysis. stdKt/V has been proposed to measure the dialysis dose in dialysis regimens with frequency independency. The Lecce experience reported a weekly Kt/V of 4.6, which is approximately an stdKt/V of 2.36, while in our study, we achieved an stdKt/V of 3.77.
The haematocrit in Lecce dialysis was significantly higher (31.1%) than that in a population from the same region on standard HD (25.7%) [8] . Excellent anaemia control has been observed in all studies of long-duration dialysis. A decrease in erythropoietin dose has been reported by Bujeja et al. [4] , David et al. [5] and Ok et al. [26] , with reductions of 2089, 1512 and 1329 UI/week, respectively. In the present study, we observed this tendency with a reduction of 1083 UI/week and, at the end of the study, ESA treatment was discontinued in 29% of the patients.
During the follow-up, bicarbonate levels significantly increased compared with baseline data. These results are supported by those of Ok et al. [26] with nocturnal dialysis and by the Lecce experience of every-other-day dialysis [8] . As expected, BUN and serum creatinine levels were also significantly reduced. The remaining biochemical parameters evaluated showed no significant changes, except for an increase in HDL levels in Group A, although a confounding factor may be that some patients in Group A started statins during the study period. Hyperphosphataemia is an independent predictor of mortality and has been associated with vascular calcification [30] . Most studies have found that phosphate removal is better with long-duration nocturnal HD than with conventional treatment because the increased time allows more efficient equilibration between the intracellular and extracellular compartments. In a case-controlled study, Powell et al. [25] observed no differences in pre-dialysis serum phosphate between conventional 4-5 h HD and 6-7 h overnight HD but did report a small decrease in phosphate binders from 92.5 to 86.8%. In a comparative trial after conversion from conventional 4-h dialysis to in-centre 7-8 h thrice-weekly nocturnal HD, Bugeja et al. [4] reported that phosphorus decreased from 5.9 to 3.7 mg/dL and the use of phosphate binders was reduced from 6.2 to 4.9 tablets/day at the end of the study. In a 655 patient cohort of in-centre long-term dialysis, Lacson et al. [24] found a significant reduction in serum phosphate of 0.2 mg/dL with no mention of phosphate binders. When comparing conventional with nocturnal HD, Ok et al. [26] found that serum phosphate levels significantly decreased (from 4.63 to 3.87 mg/dL) and that the need for phosphate binders was reduced (from 83 to 22.4%). In our study, better phosphate control was also observed (from 4.93 to 3.74 mg/dL) with a decrease in the need for phosphate binders from 77 to 4%. Moreover, in our study, the addition of phosphorus supplements in the dialysate was required in 55% of the patients. This improved phosphate control could be explained by the sum of several factors. Firstly, the dialysis dose was higher than in other studies; secondly, some studies have demonstrated that OL-HDF increases phosphate depuration with a reduction in pre-dialysis levels [31, 32] and finally, the increased frequency (every-other-day) is another advantage as studies of daily nocturnal dialysis have observed excellent phosphate control without phosphate binders and with phosphate supplementation in the dialysate [33, 34] .
Some authors have suggested that long-duration nocturnal HD could improve nutritional status through an antiinflammatory effect and increased appetite, energy and body weight [35, 36] . In a prospective evaluation of incentre nocturnal HD, David et al. [5] found a significant improvement in nutritional status assessed by body weight (1.2 kg after 12 months), body mass index, nPCR and bioelectrical impedance. Another study of long-term dialysis [26] found that body weight increased 1.8 kg in patients who completed 1 year of follow-up. In the present study, improvements in certain causes of anorexia such as better appetite, reduced fluid overload and uraemic milieu could explain these nutritional advantages with the switch to 7-8 h nocturnal every-other-day OL-HDF. Importantly, the improvement of nutrition was without Cardiovascular disease is the most common cause of mortality in chronic HD patients, being the attributed cause of death in~50%. The outline of this study has contributed greatly to reduce these cardiovascular risk factors specially the reduction pre-dialysis phosphorus levels, blood pressure control and partial regression of LVH, which confirms the importance of increasing the duration of the sessions and higher frequency. Hypertension is strongly associated with mortality and is highly prevalent in dialysis patients. It is not known for how long HD controls hypertension but has been suggested by reductions in serum norepinephrine levels and the improvement of heart rate response to pulsatile blood pressure (baroreceptor response and arterial compliance) [35] ; an additional factor is the slower ultrafiltration rate in a longer time period. Charra et al. [36] suggest that factors hampering blood pressure control are the reduction in session time, an insufficient dialysis dose and increases in salt intake. In our study, although our patients were relatively well controlled at baseline, better blood pressure control was achieved, with only 8% of patients requiring anti-hypertensive medications at the end of the study.
LVH is an independent cardiovascular risk factor and is strongly associated with mortality in dialysis patients [37] . LVH is present in 70-80% of the dialysis population [38] . Hypertension, poor extracellular fluid volume control, anaemia and uraemia (accumulation of uraemic toxins and circulatory vasoconstrictors) have been implicated in the pathophysiology of LVH. In the present study, we observed a regression of LVH with the LVMI being reduced by 12% after 1 year. Other authors have reported regression of cardiac hypertrophy measured with echocardiography. Ok et al. [26] reported an LVMI reduction of 17% in patients receiving thrice-weekly nocturnal dialysis and Chan et al. [39] reported an LVMI reduction of 22% in 28 patients receiving slow nocturnal daily dialysis.
The authors were surprised of the fact that plasma level of b 2 -microglobulin was not decreased during the follow-up in spite of a significant increase of infused volume and also by increasing time and frequency scheme. Previously published data [40] have shown that there are a direct correlation between infusion volume and b 2 -microglobulin reduction ratio but this probably does not mean that it could reduce the pre-dialysis levels. This difficulty could be also explained by the low distribution volume of b 2 -microglobulin [41] . Previous published studies have shown that predialysis levels of b 2 -microglobulin have been reduced when switching from low-flux to high-flux HD, low-flux HD to OL-HDF [42] [43] [44] , high-flux HD to OL-HDF [14, 45] , highflux HD to daily, 8 h, nocturnal high-flux HD [46] and thrice a week, 4.0-5.0 h OL-HDF to daily, 2.0-2.5 h OL-HDF [47] . However, Ok et al. [26] reported that could not reduce pre-dialysis levels of b 2 -microglobulin only changing dialysis duration. Nocturnal every-other-day OL-HDF 1629
Solute and fluid removal are the major goals of dialysis. Reduction of elevated pre-dialysis uraemic toxin levels may prevent or postpone the onset of dialysis-related complications. Resistance to diffusion within tissues and organs creates solute disequilibrium gradients. The resistance to diffusion can be quantitated as the intercompartment mass transfer coefficient (Kc) and is molecular size-sensitive. Our crossover and randomized study allowed us to observe distinct patterns of molecule removal. The change to nocturnal every-other-day OL-HDF, 7-8 h per session. In this study, increased removal in urea (13%) and creatinine (9%) were shown.
The result of b 2 -microglobulin removal, as a marker of middle molecule solutes, largely depends on convection processes. In this study, there were no differences between values at baseline and at 6 months with the same convective volume, indicating that removal of b 2 -microglobulin mainly depends on the total convective volume, independent of the dialysis time. A different pattern was demonstrated for larger molecules than b 2 -microglobulin. Plasma removal of myoglobin and prolactin reduction ratios was significantly decreased in Groups A and B in 6-month periods with the same convective volume. This finding could be explained by the different speed of infusion flow, which was 90-110 mL/min at baseline and in 6-month periods of 35-50 L convective volume but was 50-60 mL/min in 6-month periods with the same convective volume. Finally, a 1 -acid glycoprotein reduction ratios, despite increasing from 4 to 14% in this study, showed the difficulty of removing molecules with a molecular weight >40 kDa. We conclude that conversion from 4-5 h thrice-weekly OL-HDF to 7-8 h every-other-day with online HDF in a crossover study with the same or higher convective volume shows excellent clinical tolerance and patient acceptance, adequate social and occupational rehabilitation, better dialysis adequacy, remarkable improvement in nutritional status, regression of LVH, good phosphate and hypertension control and a marked reduction of phosphate binders and anti-hypertensive medication. Different patterns of solute removal were observed, which were related to dialysis time, convective volume and/or to the infusion flow rate. Therefore, long-term, nocturnal, in-centre, every-other-day and online HDF with high convective volume could be a good therapeutic dialysis model that could improve clinical and social-occupational rehabilitation.
